Evidence map›Paper›PMID 38179085›Full record

ArticleAIChE journal. American Institute of Chemical Engineers2023

Techno-economic analysis of dynamic, end-to-end optimal pharmaceutical campaign manufacturing using PharmaPy.

Daniel Casas-Orozco, Daniel Laky, Vivian Wang, Mesfin Abdi, X Feng, E Wood, Gintaras V Reklaitis, Zoltan K Nagy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIChE journal. American Institute of Chemical Engineers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniel Casas-OrozcoDavidson School of Chemical Engineering, Purdue University, West Lafayette, IN 47906, USA.
Daniel LakyDavidson School of Chemical Engineering, Purdue University, West Lafayette, IN 47906, USA.
Vivian WangOffice of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food & Drug Administration, Silver Spring, MD, USA.
Mesfin AbdiOffice of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food & Drug Administration, Silver Spring, MD, USA.
X FengOffice of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food & Drug Administration, Silver Spring, MD, USA.
E WoodOffice of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food & Drug Administration, Silver Spring, MD, USA.
Gintaras V ReklaitisDavidson School of Chemical Engineering, Purdue University, West Lafayette, IN 47906, USA.
Zoltan K NagyDavidson School of Chemical Engineering, Purdue University, West Lafayette, IN 47906, USA.

Funding

Risk-based process synthesis and Industry 4.0 framework for pharmaceutical manufacturing processesU01FD006738 · FDA · PURDUE UNIVERSITY · PI NAGY, ZOLTAN KALMAN · 2019 to 2021
$3.0M
FDA HHS U01 FD006738
6 · The paper itself

Abstract

Increased interest in the pharmaceutical industry to transition from batch to continuouos manufacturing motivates the use of digital frameworks that allow systematic comparison of candidate process configurations. This paper evaluates the technical and economic feasibility of different end-to-end optimal process configurations,

Indexed as

campaign manufacturingdigital designflowsheet optimizationhybrid processingprocess designPython

Identifiers

PMID38179085
PMCPMC10765457

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.